SCHEMBL4518797

SCHEMBL4518797

COc1c(-c2c[nH]c(N)n2)ccc2ccccc12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 10/20 0.44
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
KIT P10721 1/20 0.38
FLT4 P35916 1/20 0.38
KDR P35968 1/20 0.38
FLT3 P36888 1/20 0.38
POLB P06746 1/20 0.37
CCNT1 O60563 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CDK9 P50750 1/20 0.36
MAPT P10636 2/20 0.36
ALDH1A1 P00352 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MAPK1 P28482 1/20 0.35
HPGD P15428 1/20 0.35
NFATC1 O95644 1/20 0.34
GSK3B P49841 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4535219 0.79 IDO1 (0.49) PDGFRBMEN1KMT2AKITFLT4
SCHEMBL4530947 0.77 MEN1 (0.60) PDGFRBMEN1KMT2ACCNT1CCNA2
SCHEMBL4491315 0.77 NOS1 (0.46) PDGFRBMEN1KMT2ACCNT1CCNA2
SCHEMBL17380794 0.76 KDM4E (0.38) PDGFRBMEN1KMT2APOLBMAPT
SCHEMBL16082559 0.76 ALDH1A1 (0.54) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL4519311 0.76 KDM4E (0.43) PDGFRBMEN1KMT2AMAPTALDH1A1
SCHEMBL26905316 0.75 POLB (0.40) PDGFRBMEN1KMT2APOLBMAPT
SCHEMBL4837885 0.74 MEN1 (0.38) MEN1KMT2APOLBMAPTALDH1A1
SCHEMBL12592216 0.74 CYP1A2 (0.43) PDGFRBMEN1KMT2APOLBMAPT
SCHEMBL1408091 0.74 HSP90AA1 (0.53) MAPTALDH1A1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090018150-A1 5-Ht2b Receptor Antagonists ASTERAND UK LIMITED (GB) 2009-01-15 US disclosed
EP-1648876-A1 5-HT SB 2B /SB RECEPTOR ANTAGONISTS Pharmagene Laboratories Ltd (GB) 2006-04-26 EP disclosed
WO-2005012263-A1 5-HT2B RECEPTOR ANTAGONISTS PHARMAGENE LABORATORIES LIMITED (GB) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090018150-A1 5-Ht2b Receptor Antagonists HTR2B, HTR1B, HTR3B PDGFRB 200/4885MEN1 3047/4885KMT2A 2279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.